Biologics Research Review Issue 97 Dermatology focus
In this issue:
Serious infection risk with adalimumab for hidradenitis suppurativa
IL-17 inhibitors not associated with increased risk of early MACE
Infection risk with JAK inhibitors vs biologics for atopic dermatitis
Amlitelimab for atopic dermatitis
Biologics for paediatric plaque psoriasis
Ustekinumab biosimilar, BAT2206, for moderate-to-severe psoriasis
Biologic therapy and malignancy risk in psoriasis
Real-world outcomes of bimekizumab for psoriasis
Optimal sequential therapy after secondary IL-17A inhibitor failure
Kuwait consensus statements on biologics for chronic plaque psoriasis
Expert contributor
Associate Professor Annika Smith
Dr Annika Smith is a Fellow of the Australasian College of Dermatologists and Consultant Dermatologist in public and private settings in Sydney. Annika undertook training at the prestigious St John’s Institute of Dermatology London, followed by further sub-specialty training in New York. Annika has a special interest in complex medical dermatology, including clinical and research […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.